17.96
1.53%
+0.27
Pre-market:
18.00
0.04
+0.22%
Guardant Health Inc stock is currently priced at $17.96, with a 24-hour trading volume of 2.74M.
It has seen a +1.53% increased in the last 24 hours and a -8.04% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $17.46 pivot point. If it approaches the $18.00 resistance level, significant changes may occur.
Guardant Health Inc Stock (GH) Financials Data
Guardant Health Inc (GH) Revenue 2023
GH reported a revenue (TTM) of $563.95 million for the quarter ending December 31, 2023, a +25.45% rise year-over-year.
Guardant Health Inc (GH) Net Income 2023
GH net income (TTM) was -$479.45 million for the quarter ending December 31, 2023, a +26.76% increase year-over-year.
Guardant Health Inc (GH) Cash Flow 2023
GH recorded a free cash flow (TTM) of -$345.46 million for the quarter ending December 31, 2023, a +10.72% increase year-over-year.
Guardant Health Inc (GH) Earnings per Share 2023
GH earnings per share (TTM) was -$4.28 for the quarter ending December 31, 2023, a +33.12% growth year-over-year.
Guardant Health Inc Stock (GH) Latest News
Insiders Buying Advance Auto Parts And 2 Other Stocks
Benzinga
Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test
Benzinga
4 Analysts Have This To Say About Guardant Health
Benzinga
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
Zacks Investment Research
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Cap:
|
Volume (24h):